



US009409965B2

(12) **United States Patent**
Beldegrun et al.

(10) **Patent No.:** **US 9,409,965 B2**
(45) **Date of Patent:** ***Aug. 9, 2016**

(54) **KIDNEY-SPECIFIC TUMOR VACCINE
DIRECTED AGAINST KIDNEY TUMOR
ANTIGEN G-250**

(71) Applicant: **The Regents of the University of
California, Oakland, CA (US)**

(72) Inventors: **Arie Beldegrun, Los Angeles, CA
(US); Cho-Lea Tso, Torrance, CA (US)**

(73) Assignee: **The Regents of the University of
California, Oakland, CA (US)**

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **14/268,662**

(22) Filed: **May 2, 2014**

(65) **Prior Publication Data**

US 2015/0010587 A1 Jan. 8, 2015

Related U.S. Application Data

(60) Continuation of application No. 12/479,415, filed on
Jun. 5, 2009, now Pat. No. 8,741,306, which is a
division of application No. 09/783,708, filed on Feb.
13, 2001, now Pat. No. 7,572,891.

(60) Provisional application No. 60/182,429, filed on Feb.
14, 2000, provisional application No. 60/182,636,
filed on Feb. 15, 2000.

(51) **Int. Cl.**

A61K 39/00 (2006.01)
C07K 1/00 (2006.01)
C07K 14/00 (2006.01)
C07K 14/535 (2006.01)
C07K 14/47 (2006.01)
A61K 38/00 (2006.01)

(52) **U.S. Cl.**

CPC **C07K 14/535** (2013.01); **A61K 39/0011**
(2013.01); **C07K 14/47** (2013.01); **C07K**
14/4748 (2013.01); **A61K 38/00** (2013.01);
A61K 2039/5154 (2013.01); **A61K 2039/5158**
(2013.01); **A61K 2039/53** (2013.01); **A61K**
2039/55516 (2013.01); **A61K 2039/55522**
(2013.01); **A61K 2039/6031** (2013.01)

(58) **Field of Classification Search**

CPC **A61K 39/00**; **A61K 39/0005**; **A61K**
39/0011; **A61K 2039/51**; **A61K 2039/5154**;
A61K 2039/5158; **A61K 2039/555**; **A61K**
2039/55511; **A61K 2039/55516**; **A61K**
2039/55522

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,616,477 A 4/1997 Price
5,972,353 A 10/1999 Zavada et al.
7,250,291 B1 7/2007 Dranoff et al.
7,572,891 B2 8/2009 Beldegrun et al.
8,711,306 B2 4/2014 Oohira et al.

FOREIGN PATENT DOCUMENTS

WO 95/34650 A2 12/1995
WO 95/34650 A3 12/1995
WO 2005/037083 A2 4/2005
WO 2005/037083 A3 4/2005

OTHER PUBLICATIONS

Luo et al. Synthetic DNA delivery systems. Nature Biotechnology
18, 33-37 (2000).*

Batova et al. (1999) "The Ch14.18-GM-CSF Fusion Protein Is Effective
at Mediating Antibody-dependent Cellular Cytotoxicity and
Complement-dependent Cytotoxicity in Vitro" Clin. Cancer Res.,
5:4256-4263.

Battaglia et al. (2000) "The fusion protein MEN 11303 (granulocyte-
macrophage colony stimulating factor/erythropoietin) acts as a
potent inducer of erythropoiesis" Exp. Hematol., 28:490-498.

Bhattacharya-Chatterjee M et al Curr Opin Mol Ther. Feb.
2001;3(1):63-9).

Bowne et al. (1999) "Injection of DNA encoding granulocyte-
macrophage colony stimulating factor recruits dendritic cells for
immune adjuvant effects" Cytokines Cellu. Mol Ther., 5:217-225.

Brändle et al. (1996) "A Mutated HLA-A2 Molecule Recognized by
Autologous Cytotoxic T Lymphocytes on a Human Renal Cell Car-
cinoma" J. Exp. Med., 183:2501-2508.

Brossart et al. (1998) "Her-2/neu-derived peptides are tumor-associ-
ated antigens expressed by human renal cell and colon carcinoma
lines and are recognized by in vitro induced specific cytotoxic T
lymphocytes" Cancer Res., 58:732-736.

Cao et al. (1999) "Therapy of established tumour with a hybrid
cellular vaccine generated by using granulocyte-macrophage colony
stimulating factor genetically modified dendritic cells" Immunol.,
97:616-625.

Condon et al. (1996) "DNA-based immunization by in vivo transfec-
tion of dendritic cells" Nature Med., 2(10):1122-1128.

Fisher et al. (1997) "High-Dose Aldesleukin in Renal Cell Carci-
noma: Long Term Survival Update" Cancer J. Sci. Amer., 3: S70.

Gaugler et al. (1996) "A new gene coding for an antigen recognized
by autologous cytolytic T lymphocytes on a human renal carcinoma"
Immunogenetics, 44:323-330.

(Continued)

Primary Examiner — Alana Harris Dent

(74) *Attorney, Agent, or Firm* — Kilpatrick Townsend &
Stockton LLP

(57) **ABSTRACT**

This invention provides an anti-cancer immunogenic agent(s)
(e.g. vaccines) that elicit an immune response specifically
directed against renal cell cancers expressing a G250 anti-
genic marker. Preferred immunogenic agents comprise a chi-
meric molecule comprising a kidney cancer specific antigen
(G250) attached to a granulocyte-macrophage colony stimu-
lating factor (GM-CSF). The agents are useful in a wide
variety of treatment modalities including, but not limited to
protein vaccination, DNA vaccination, and adoptive immu-
notherapy.

14 Claims, 12 Drawing Sheets